https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-08 08:41:162026-01-08 08:41:16STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications
https://www.optimumcomms.com/wp-content/uploads/2023/02/ViCentra_Logo_300x180px-3.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-08 08:00:562026-01-08 08:01:42ViCentra Expands Financing to $98 Million to Accelerate European Commercialization and Ready Next Generation Kaleido Insulin Patch Pump System for U.S. Access
https://www.optimumcomms.com/wp-content/uploads/2026/01/Tecregen_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-08 08:00:002026-01-08 12:48:45TECregen Raises CHF 10 Million in Seed Financing and Appoints Dr. Bo Rode Hansen as Chairman
https://www.optimumcomms.com/wp-content/uploads/2023/06/Synaffix_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-07 09:22:412026-01-07 15:55:19Lonza’s Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next‑Generation Bispecific ADCs
https://www.optimumcomms.com/wp-content/uploads/2026/01/Nucleome_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-07 09:03:292026-01-07 09:03:29Nucleome Therapeutics nominates first preclinical development candidate
https://www.optimumcomms.com/wp-content/uploads/2025/04/AstronauTx_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-07 08:33:422026-01-07 08:33:42AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board
https://www.optimumcomms.com/wp-content/uploads/2026/01/Acension_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-06 10:56:522026-01-06 10:56:52Acesion Pharma starts Phase 2 trial of AP31969 in patients with atrial fibrillation
https://www.optimumcomms.com/wp-content/uploads/2024/10/Loqus23_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-06 08:37:282026-01-06 08:37:28LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington’s Disease
https://www.optimumcomms.com/wp-content/uploads/2025/12/Numares_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-12-17 10:05:592025-12-17 10:05:59numares Health enters ASEAN region with regulatory approval in Malaysia and first contract win for AXINON ® LDLp Test System
https://www.optimumcomms.com/wp-content/uploads/2025/08/Leucid_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-12-15 13:36:192025-12-15 13:36:19Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering
https://www.optimumcomms.com/wp-content/uploads/2024/04/Fibrocor_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-12-09 09:02:532025-12-09 09:04:02Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-12-08 07:14:122025-12-08 07:14:12Poolbeg Pharma plc – POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-12-08 06:50:182025-12-08 08:52:55Oncoinvent announces publication of Phase 1 study results for Radspherin® in ovarian cancer in Gynecologic Oncology
https://www.optimumcomms.com/wp-content/uploads/2025/07/Actithera-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-12-03 08:34:202025-12-03 08:34:20Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer
https://www.optimumcomms.com/wp-content/uploads/2024/04/Xeltis_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-12-02 08:58:472025-12-02 08:58:47Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-27 09:00:302025-11-27 10:45:03Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures
https://www.optimumcomms.com/wp-content/uploads/2023/02/Biocomposites_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-25 08:59:092025-11-25 11:13:10Biocomposites announces expanded approval for STIMULAN® Rapid Cure to be mixed with antimicrobials to treat infection
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-20 08:34:592025-11-20 08:34:59Poolbeg Pharma plc – POLB 001 European Patent granted
https://www.optimumcomms.com/wp-content/uploads/2023/02/Sofinnova_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-17 06:38:372025-11-17 06:38:37Sofinnova Partners closes €650M ($750M) Capital XI, greatly exceeding initial target to back early-stage healthcare deals
https://www.optimumcomms.com/wp-content/uploads/2023/02/Medicxi_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-11-14 09:25:312025-11-14 09:26:45Medicxi Announces €500 Million Fund VFor more information about Optimum Strategic Communications, please get in touch.
